• Written informed consent

• Participant must be 12 to 75 years of age

• Documented history of physician-diagnosed asthma requiring treatment with at least medium-dose ICS (\> 250 μg fluticasone dry powder formulation equivalents total daily dose) and a LABA, for at least 12 months prior to Visit (V) 1.

• Documented treatment with medium-dose ICS and LABA for at least 3 months prior to Visit 1 with or without additional asthma controllers (excluding oral corticosteroids).

• Weight of ≥ 35 kg.

• Pre-Bronchodilator (BD) Forced expiratory volume in 1 second (FEV1) of ≤ 90% predicted

• Documented at least 2 asthma exacerbations in the 12 months prior to the date of informed consent.

• ACQ-6 score ≥ 1.5 at Visit 1, plus at least once in the run-in period (from V2 to V3) and at V3.

• Evidence of asthma as documented by excessive variability in lung function, as defined in the protocol.

• Peripheral blood eosinophil count of ≥ 150 cells/μL, as defined in the protocol.

• At least 70% compliance with usual asthma controller ICS-LABA during run-in period (from Visit 2 to Visit 3) based on asthma daily diary.